Advertisement

Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures

      Abstract

      Background

      Spinal analgesia is recommended for intractable cancer pain. Morphine-clonidine and sufentanil-clonidine are often used in association in intrathecal drug delivery systems, injected by intraabdominal pumps. To refill these pumps and to limit patient transport, it may be necessary to ship the mixtures in polypropylene syringes to peripheral establishments located near patient homes. The purpose of this study is to determine the stability of morphine-clonidine and sufentanil-clonidine mixtures in polypropylene syringes to ensure the best and safest transport conditions and in implantable pumps for intrathecal use.

      Materials and Methods

      The stability study method was conceived according to the International Council for Harmonization guidelines. For polypropylene syringes, four different mixtures of morphine-clonidine and sufentanil-clonidine were assessed over seven days. Two storage temperatures were tested (5 ± 3 °C and 25 ± 2 °C). For implantable pumps, two different mixtures of morphine-clonidine and sufentanil-clonidine were assessed over 28 days and stored at 37 °C.

      Results

      For the morphine-clonidine mixtures in polypropylene syringes, all mixtures remained stable for five days in both storage conditions (5 ± 3 °C and 25 ± 2 °C) because of relative concentrations systematically positioned between 90% and 110% (95% CIs of the mean of three samples). The two mixtures in implantable pumps remained stable for 28 days.
      For the sufentanil-clonidine mixtures in polypropylene syringes, cold conservation kept all the preparations stable for seven days, whereas a quick degradation was observed after only two days for ambient storage conditions. This result is similar to that with an implantable pump, in which the concentration is <90% on day 7 for low concentration mixtures.
      No visual modification, no significant pH modification, and no changes in turbidity assays were observed in either study.

      Conclusion

      This study shows the stability of the morphine-clonidine mixtures in syringes stored at 5 °C for five days and in implantable pumps stored at 37 °C for 28 days. For the sufentanil-clonidine mixtures, the results show stability in syringes for seven days at 5 °C. Pump results show stability of seven days for low concentrations and 28 days for high concentrations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization. Accessed August 19, 2022.
        • Bottros M.M.
        • Christo P.J.
        Current perspectives on intrathecal drug delivery.
        J Pain Res. 2014; 7: 615-626https://doi.org/10.2147/JPR.S37591
        • Lamer T.J.
        Treatment of cancer-related pain: when orally administered medications fail.
        Mayo Clin Proc. 1994; 69: 473-480https://doi.org/10.1016/S0025-6196(12)61647-4
        • Sukul V.V.
        Intrathecal pain therapy for the management of chronic noncancer pain.
        Neurosurg Clin N Am. 2019; 30: 195-201https://doi.org/10.1016/j.nec.2018.12.010
        • Rezai A.
        • Kloth D.S.
        • Hansen H.
        • Schultz D.M.
        • Thompson S.
        • Deer T.R.
        Physician response to Medtronic’s position on the use of off-label medications in the synchromed pump.
        Pain Phys. 2013; 16: 415-417
        • Maves T.J.
        • Gebhart G.F.
        Antinociceptive synergy between intrathecal morphine and lidocaine during visceral and somatic nociception in the rat.
        Anesthesiology. 1992; 76: 91-99https://doi.org/10.1097/00000542-199201000-00014
        • Penning J.P.
        • Yaksh T.L.
        Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat.
        Anesthesiology. 1992; 77: 1186-2000
        • Deer T.R.
        • Levy R.
        • Prager J.
        • et al.
        Polyanalgesic Consensus Conference—2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain.
        Neuromodulation. 2012; 15 ([discussion: 482]. https://dx.doi.org/10.1111/j.1525-1403.2012.00486.x): 467-482
        • Deer T.R.
        • Pope J.E.
        • Hayek S.M.
        • et al.
        The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines.
        Neuromodulation. 2017; 20: 96-132https://doi.org/10.1111/ner.12538
        • Robert J.
        • Sorrieul J.
        • Pluchon Y.M.
        • Dupoiron D.
        • Devys C.
        État des lieux interrégionaux de l’analgésie intrathécale—analyses et perspectives.
        Douleurs: Évaluation - Diagnostic - Traitement. 2019; 20: 109-116https://doi.org/10.1016/j.douler.2019.04.002
        • Sorrieul J.
        • Robert J.
        • Kieffer H.
        • Folliard C.
        • Devys C.
        Feedback on the centralization of intrathecal analgesic preparations in hospital pharmacy.
        Pharm Technol Hosp Pharm. 2018; 3: 177-182https://doi.org/10.1515/pthp-2018-0017
        • Wang J.K.
        • Nauss L.A.
        • Thomas J.E.
        Pain relief by intrathecally applied morphine in man.
        Anesthesiology. 1979; 50: 149-151https://doi.org/10.1097/00000542-197902000-00013
        • Grass J.A.
        Sufentanil: clinical use as postoperative analgesic—epidural/intrathecal route.
        J Pain Symptom Manage. 1992; 7: 271-286https://doi.org/10.1016/0885-3924(92)90061-L
        • Jarrott B.
        • Conway E.L.
        • Maccarrone C.
        • Lewis S.J.
        Clonidine : understanding its disposition, sites and mechanism of action.
        Clin Exp Pharmacol Physiol. 1987; 14: 471-479https://doi.org/10.1111/j.1440-1681.1987.tb00999.x
        • Eisenach J.C.
        • DuPen S.
        • Dubois M.
        • Miguel R.
        • Allin D.
        • Epidural Clonidine Study Group
        Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group.
        Pain. 1995; 61: 391-399https://doi.org/10.1016/0304-3959(94)00209-W
        • Eisenach J.
        • Detweiler D.
        • Hood D.
        Hemodynamic and analgesic actions of epidurally administered clonidine.
        Anesthesiology. 1993; 78: 277-287https://doi.org/10.1097/00000542-199302000-00011
        • Ma C.
        • Decarie D.
        • Ensom M.H.H.
        Stability of clonidine suspension in oral plastic syringes.
        Am J Health Syst Pharm. 2014; 71: 657-661https://doi.org/10.2146/ajhp130480
        • Lu D.
        • Harmanjeet H.
        • Wanandy T.
        • Paine M.
        • Peterson G.M.
        • Patel R.P.
        Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome.
        J Clin Pharm Ther. 2019; 44: 883-887https://doi.org/10.1111/jcpt.13008
        • Xu Q.A.
        • Trissel L.A.
        • Pham L.
        Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes.
        Int J Pharm Compd. 2002; 6: 66-69
        • Hildebrand K.R.
        • Elsberry D.D.
        • Hassenbusch S.J.
        Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system.
        J Pain Symptom Manage. 2003; 25: 464-471https://doi.org/10.1016/S0885-3924(03)00041-1
        • Bianchi F.
        • Ginggen A.
        • Tardy Y.
        Stability and compatibility of drug mixtures in an implantable infusion system.
        Anaesthesia. 2008; 63: 972-978https://doi.org/10.1111/j.1365-2044.2008.05516.x
        • Nemec K.
        • Kopelent-Frank H.
        • Greif R.
        Standardization of infusion solutions to reduce the risk of incompatibility.
        Am J Health Syst Pharm. 2008; 65: 1648-1654https://doi.org/10.2146/ajhp070471
        • Jäppinen A.
        • Turpeinen M.
        • Kokki H.
        • et al.
        Stability of sufentanil and levobupivacaine solutions and a mixture in a 0.9% sodium chloride infusion stored in polypropylene syringes.
        Eur J Pharm Sci. 2003; 19: 31-36
        • Roos P.J.
        • Glerum J.H.
        • Meilink J.W.
        Stability of sufentanil citrate in a portable pump reservoir, a glass container and a polyethylene container.
        Pharm Weekbl Sci. 1992; 14: 196-200
      2. International Conference on Harmonisation. Q2 (R1): validation of analytical procedures: text and methodology. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines. Somatek Inc; 2015:1–13. Accessed August 19, 2022. http://www.ich.org/products/guideline.

      3. Guide méthodologique des études de stabilité des préparations. Partie 1: Préparations liquides. Brossard D, Chedru-Legros V, Crauste-Manciet S, et al. Accessed August 19, 2022.
        • Vigneron J.
        • Astier A.
        • Trittler R.
        • et al.
        SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update.
        Ann Pharm Fr. 2013; 71: 376-389https://doi.org/10.1016/j.pharma.2013.06.002
        • Robert J.
        • Sorrieul J.
        • Kieffer H.
        • et al.
        Stability study of morphine and baclofen solution in polypropylene syringes.
        Pharm Technol Hosp Pharm. 2017; 2https://doi.org/10.1515/pthp-2017-0028
        • Sorrieul J.
        • Robert J.
        • Gibory V.
        • et al.
        Stability of sufentanil and baclofen mixtures for intrathecal analgesia at different concentrations in polypropylene syringes.
        Ann Pharm Fr. 2018; 76: 444-452https://doi.org/10.1016/j.pharma.2018.05.002
        • Classen A.M.
        • Wimbish G.H.
        • Kupiec T.C.
        Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.
        J Pain Symptom Manage. 2004; 28: 603-611https://doi.org/10.1016/j.jpainsymman.2004.04.011
        • Bourdon F.
        • Simon N.
        • Lannoy D.
        • et al.
        Quality control and stability of ketamine, remifentanil, and sufentanil syringes in a pediatric operating theater.
        Paediatr Anaesth. 2019; 29: 193-199https://doi.org/10.1111/pan.13563
        • Boitquin L.P.
        • Hecq J.D.
        • Vanbeckbergen D.F.
        • Jamart J.
        • Galanti L.M.
        Stability of sufentanil citrate with levobupivacaine HCl in NaCl 0.9% infusion after microwave freeze-thaw treatment.
        Ann Pharmacother. 2004; 38: 1836-1839https://doi.org/10.1345/aph.1D564
        • Hecq J.D.
        • Samson M.
        • Moyson J.
        • Geerts P.
        Sufentanyl : Stability and Compatibility Data.
        1st ed. Belgian Association of Hospital Pharmacy and Jansen-Cilag, Beerse, Belgium1995
        • Shields D.E.
        • Aclan J.
        • Szatkowski A.
        Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration.
        Int J Pharm Compd. 2008; 12: 463-466